The diagnostic efficacy of nectin 4 expression in ovarian cancer patients

Biomarkers

Volumn 19, Issue 6, 2014, Pages 498-504

  Nabih, Enas Samir ^a   Abdel Motaleb, Fayda Ibrahim ^a   Salama, Fekria Ahmed ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

CA 125; Marker; Nectin 4; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; MESSENGER RNA; NECTIN 4; TUMOR MARKER; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; LNIR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906334407     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.940503     Document Type: Article

References (14)

1. American Cancer Society (ACS). (2012). Cancer facts and figures. Atlanta (GA): American Cancer Society.
2. Bast Jr RC, Feeney M, Lazarus H, et al. (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-7.
3. De Rycke MS, Pambuccian SE, Gilks CB, et al. (2010). Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 134:835-45.
4. Fabre-Lafay S, Garrido-Urbani S, Reymond N, et al. (2005). Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-a-converting enzyme (TACE)/ADAM-17. J Biol Chem 280:19543-50.
5. Fabre-Lafay S, Monville F, Garrido-Urbani S, et al. (2007). Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 7:73.
6. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr [last accessed 13 Dec 2013].
7. Fournier G, Garrido-Urbani S, Reymond N, Lopez M. (2010). Nectin and nectin-like molecules as markers, actors and targets in cancer. Med Sci (Paris) 26:273-9.
8. Fritsche HA, Bast RC. (1998). CA 125 in ovarian cancer: advances and controversy. Clin Chem. 44:1379-80.
9. Mahdy NH, Abdel-Fattah M, Ghanem H. (1999). Ovarian cancer in Alexandria from1988 to 1997: trends and survival. East Mediterr Health J 5:727-39.
10. Miyoshi J, Takai Y. (2007). Nectin and nectin-like molecules: biology and pathology. Am J Nephrol 27:590-604.
11. Ogita H, Takai Y. (2006). Nectins and nectin-like molecules: roles in cell adhesion, polarization, movement, and proliferation. IUBMB Life 58:334-43.
12. Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB. (2011). Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 4:15-21.
13. Takai Y, Miyoshi J, Ikeda W, Ogita H. (2008). Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 9:603-15.
14. Takano A, Takano A, Ishikawa N, et al. (2009). Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 69:6694-703.